US$ 100 million credit facility from ING

EQS Newswire / 22/07/2025 / 10:14 MSK Solidcore Resources plc (“Solidcore” or the “Company”) is pleased to announce that it has entered into a credit facility agreement with Dutch bank ING for up to US$ 100 million. The Company aims to use the funds for general corporate purposes, including the…

Simply Wall Street Releases July 2025 Global Top 10 Undiscovered Gems: UJU Holding (1948.HK) Secures Spot with Strong Fundamentals

EQS Newswire / 17/07/2025 / 17:24 UTC+8 As global markets experience a surge, with the S&P 500 and Nasdaq Composite hitting record highs and smaller-cap indexes like the S&P MidCap 400 and Russell 2000 outperforming, investors are keenly observing economic indicators such as resilient job growth and fluctuating manufacturing activity.…

Drug, Medical Device and Aesthetics, 肌顏態 was displayed at the CSD2025, The GeneQueens and 金因敷 launch was grandly held in Changsha

EQS Newswire / 02/07/2025 / 09:56 UTC+8          On June 27, 2025, Uni-Bio Science Group Limited (the “Group”)grandly held a new medical aesthetics product launch event in Changsha, releasing the high-end series GeneQueens of 肌顏態® and the medical device brand 金因敷®. Many experts, KOLs and partners attended the event. This launch not…

Hong Kong’s First Embodied AI Humanoid Robot Company Launches! HK ROBOTICS (00370.HK) Successfully Hosts Industry Forum and Brand Strategy Launch Event

EQS Newswire / 17/06/2025 / 15:21 UTC+8 HONG KONG, June 16, 2025 — Hong Kong's first embodied AI humanoid robot company, Hong Kong Robotics Group Holding Limited (HK ROBOTICS, stock code: 00370.HK), grandly held the "Hong Kong Intelligent Robotics Development Prospects Forum and HK ROBOTICS Embodied AI Brand Strategy Launch Event" at…

Chow Tai Fook Jewellery Posts Strong Margin Expansion and Operating Profit for FY2025 from Brand Transformation Success

EQS Newswire / 12/06/2025 / 18:58 UTC+8 Results Highlights Macro-economic externalities and elevated gold prices weighed on the consumer sentiment in FY2025. The Group’s revenue decreased by 17.5% year-on-year to HK$89,656 million. Nonetheless, operating profit remained resilient, with a year-on-year growth of 9.8%, reaching HK$14,746 million. Operating profit margin expanded…

MegaPro Unveils Promising Phase I Results for Tween-80-Free Anti-Cancer Drug MPB-1734

EQS Newswire / 10/06/2025 / 14:28 UTC+8 Taipei, June 10, 2025 — MegaPro Biomedical Co., Ltd. (hereafter referred to as “MegaPro” , TWSE: 6827), a clinical-stage biopharmaceutical company, today announced strong Phase I clinical results for its next-generation anti-cancer drug, MPB-1734. Developed using MegaPro’s proprietary nano-micelle platform, MPB-1734 is a…